Hosted on MSN

FDA grants expanded access to ImmunityBio’s Anktiva for lymphopenia

The US Food and Drug Administration (FDA) has granted expanded access authorisation for ImmunityBio’s Cancer BioShield platform, anchored by Anktiva (nogapendekin alfa inbakicept-pmln), to treat ...
News Medical

How does SARS-CoV-2 cause lymphopenia when T cells barely express ACE-2 receptors?

In a recent review published in the journal Cell Communication and Signaling, a team of researchers in Egypt and the United States explored the direct and indirect mechanisms of T lymphocyte-linked ...
Nasdaq

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

While Epogen and Neupogen addresses anemia and neutropenia, no therapy has existed for the treatment of lymphopenia until ANKTIVA® –The Cancer BioShield. Landmark overall survival benefit (P-value ...
Seeking Alpha

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (IBRX), a leading immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access ...